An observational study (GEICO 87-R) was performed in high-grade ovarian cancer patients treated within the rucaparib access program (RAP) in Spain. The aim was to better understand rucaparib's management in real-life setting, to optimize future use, considering Pt-sensitive and Pt-resistant BRCAmut treatment and maintenance patients.
A retrospective study was performed at 22 GEICO hospitals in Spain that treated patients within RAP (600 mg BID) since September 2018. Adult women with high-grade epithelian ovarian, fallopian tube, or primary peritoneal cancer, with medical record available, were included. Patient characteristics, medical history, safety, efficacy, and dosing data were collected.
The setting of this observational study was rucaparib's access program (RAP) in Spain, in the context of real-life use of the product.
